Sharemaestro Newsreel

Pfizer’s oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer announced that its oral drug Litfulo successfully restored skin pigmentation in patients with nonsegmental vitiligo during two late-stage trials. The drug significantly improved facial and total-body repigmentation, paving the way for global regulatory submissions. Litfulo, which blocks specific immune cell proteins, is already …

Bristol-Myers stock gains after Q2 2026 beat (BMY:NYSE)

Bristol-Myers Squibb (BMY) raised its full-year outlook after reporting better-than-expected Q2 2026 financials, driven by strong sales of its cancer therapies. The company reported approximately $13.0B in revenue, a ~6% YoY growth. The updated guidance for full-year revenue is $49.0B–$50.0B and adjusted EPS is …

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Pfizer announced positive topline results from two Phase 3 trials (TRANQUILLO and TRANQUILLO 2) evaluating LITFULO (ritlecitinib) for nonsegmental vitiligo (NSV). The studies demonstrated significant improvements in facial and total body repigmentation compared to placebo, meeting their co-primary endpoints. Based on these findings, Pfizer …

Bristol Myers Raises Guidance After Record-Breaking Sales

Bristol Myers Squibb Co. increased its sales and profit outlook for 2026 following better-than-expected second-quarter demand for its drugs, particularly newer treatments for heart conditions and cancer. The company now expects full-year sales between $49 billion and $50 billion, up from an earlier forecast, …

Guggenheim reiterates Biogen stock rating on stabilized revenue

Guggenheim reiterated a Buy rating and $280 price target on Biogen Inc. following strong quarterly results that surpassed Wall Street expectations, with revenues stabilizing after genericization headwinds. The firm believes Biogen is set for sustainable growth due to its scaled growth portfolio, the Apellis …

BRISTOL-MYERS SQUIBB ($BMY) Releases Q2 2026 Earnings

Biogen’s 68% surge validates InvestingPro Fair Value analysis By Investing.com

InvestingPro's Fair Value models identified Biogen (NASDAQ:BIIB) as undervalued nearly a year ago, predicting a significant upside. The stock subsequently surged by over 67%, reaching and exceeding the initial Fair Value target, validating InvestingPro's analytical approach. This success highlights how comprehensive valuation analysis can …

Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma

This article analyzes Pfizer (PFE) and Eli Lilly (LLY) as contrasting investment opportunities within the pharmaceutical sector. Pfizer is presented as a value and income play due to its low valuation and high dividend yield, despite challenges like declining COVID-19 product sales and patent …

Bristol Myers Lifts Outlook as Profit, Revenue Rise

Bristol Myers Squibb raised its full-year earnings and revenue outlook after reporting increased profit and revenue in the latest quarter. The biopharmaceutical company now forecasts earnings of $6.75 to $7 per share and revenue of $49 billion to $50 billion, an increase from its …

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers Squibb significantly raised its full-year revenue and profit forecasts for 2026 after reporting strong second-quarter results, driven by robust sales of blood thinner Eliquis and newer drugs like Camzyos and Reblozyl. The company's strategy to counter sales declines from older medicines facing …

Gilead Stock: Buy The Distortion Before Q2 Clears It Up (NASDAQ:GILD)

Gilead Sciences (GILD) is presented as a strong buy, despite a temporary $11.5 billion impairment, research, and development (IPR&D) charge that may negatively impact short-term optics but not the company's long-term fundamentals. The article highlights GILD's growing HIV franchise, its emerging oncology pipeline driven …

UBS Adjusts Price Target on Biogen to $240 From $225, Maintains Buy Rating

UBS has increased its price target for Biogen (BIIB) to $240, up from the previous $225, while reiterating a "Buy" rating for the pharmaceutical company. This adjustment comes amidst other analyst revisions, including RBC trimming its price target to $240 and JPMorgan lifting its …

Kentucky Retirement Systems Has $29.02 Million Holdings in Merck & Co., Inc. $MRK

Kentucky Retirement Systems significantly increased its stake in Merck & Co., Inc. (NYSE:MRK) by 52.5% in the first quarter, now holding 241,239 shares valued at $29.02 million. This substantial investment makes Merck & Co., Inc. the 19th largest holding for Kentucky Retirement Systems, comprising …

Kentucky Retirement Systems Buys 28,492 Shares of Amgen Inc. $AMGN

Kentucky Retirement Systems significantly increased its stake in Amgen Inc. by 84.4% in the first quarter, acquiring an additional 28,492 shares, bringing its total holdings to 62,262 shares valued at $21.9 million. Other institutional investors also adjusted their positions in Amgen. The article also …

Hamilton Wealth LLC Grows Stake in Amgen Inc. $AMGN

Hamilton Wealth LLC significantly increased its stake in Amgen (NASDAQ:AMGN) by 375.6% during the first quarter, now holding 3,405 shares valued at approximately $1.2 million. The medical research company exceeded first-quarter earnings and revenue expectations, reporting an adjusted EPS of $5.15 and $8.62 billion …

OGN|Organon & Co|Price:13.550|Chg%:+0.030

Organon & Co (OGN) stock currently trades at $13.545, with its fundamentals described as stable and growth potential high. TradingKey rates its valuation as "fairly valued" within the Pharmaceuticals industry, although it notes the stock is considered overvalued based on its PE ratio. Institutional …

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

Bristol-Myers Squibb (NYSE:BMY) reported strong Q2 CY2026 financial results, surpassing analyst expectations for both revenue and non-GAAP profit. The company's revenue grew 5.7% year-on-year to $12.97 billion, and its full-year revenue guidance of $49.5 billion also exceeded estimates. Despite strong quarterly performance, the company …

Strategic Investment Advisors MI Purchases 2,662 Shares of Amgen Inc. $AMGN

Strategic Investment Advisors MI increased its stake in Amgen Inc. by 50% during the first quarter, purchasing an additional 2,662 shares. The fund's total holdings in Amgen are now valued at $2.81 million. The article also provides a news roundup for Amgen, covering positive …

Oddo BHF Asset Management Sas Sells 50,742 Shares of Merck & Co., Inc. $MRK

Oddo BHF Asset Management Sas significantly reduced its stake in Merck & Co., Inc. by selling 50,742 shares, decreasing its holdings by 49.4% in the first quarter. Despite this, other institutional investors have increased their positions in Merck, and the company has received multiple …

South Dakota Investment Council Decreases Stock Position in Merck & Co., Inc. $MRK

The South Dakota Investment Council reduced its stake in Merck & Co., Inc. by 11.1% in the first quarter of 2026, selling 22,492 shares but retaining 179,966 shares valued at approximately $21.6 million. Despite this decrease, institutional investors collectively own 76.07% of Merck's stock. …

Amgen Inc. $AMGN Shares Purchased by Lazard Asset Management LLC

Lazard Asset Management LLC increased its stake in Amgen Inc. by 14.7% in the first quarter, now owning 50,478 shares valued at $17.76 million. Other institutional investors like Vanguard Group Inc., State Street Corp, Capital World Investors, Geode Capital Management LLC, and Norges Bank …

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen Inc. (AMGN) has outperformed the broader S&P 500 Index over the past year and year-to-date, though it underperformed the Invesco Pharmaceuticals ETF over the past year. Analysts mostly have a "Moderate Buy" rating on AMGN stock, with a Street-high price target suggesting potential …

Eli Lilly taps local manufacturer to boost obesity and diabetes meds

Eli Lilly and drug manufacturer Resilience are investing $750 million to expand Resilience's Blue Ash operations in Greater Cincinnati, aiming to significantly boost the production of KwikPens for Eli Lilly's popular diabetes and obesity medications like Mounjaro and Zepbound. This expansion is expected to …

Edgestream Partners L.P. Buys Shares of 154,427 Bristol Myers Squibb Company $BMY

Edgestream Partners L.P. has acquired a new position in Bristol Myers Squibb Company (NYSE:BMY), purchasing 154,427 shares valued at approximately $9.366 million during the first quarter. This increased institutional ownership in the biopharmaceutical company, with other major investors like Vanguard Group Inc., State Street …

Bull Harbor Capital LLC Makes New Investment in Merck & Co., Inc. $MRK

Bull Harbor Capital LLC has initiated a new position in Merck & Co., Inc. (NYSE:MRK) during the first quarter, purchasing 23,691 shares valued at approximately $2.85 million. This investment accounts for 0.8% of Bull Harbor Capital LLC's total holdings, making Merck its 16th largest …

EverSource Wealth Advisors LLC Boosts Stake in Merck & Co., Inc. $MRK

EverSource Wealth Advisors LLC significantly increased its stake in Merck & Co., Inc. (NYSE:MRK) during the first quarter, acquiring an additional 7,830 shares to own a total of 31,032 shares valued at $3,733,000. Other institutional investors like Brighton Jones LLC and Sivia Capital Partners …

Gilead (GILD) Stock Stays Cheap On Its 130% Five Year Run

Gilead Sciences (GILD) stock has seen a 130.1% return over the past five years, prompting investors to assess its current valuation. Despite this strong performance, the stock appears undervalued on earnings multiples, trading at a P/E of 17.9x compared to an estimated fair P/E …

What Analyst Projections for Key Metrics Reveal About Amgen (AMGN) Q2 Earnings

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates

Bristol Myers Squibb Lifts Full-Year Guidance After Strong Second-Quarter Earnings Beat

Sanofi (Nasdaq: SNY) lifts H1 2026 sales but books large amlitelimab hit

Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks

Sanofi ADR earnings beat by $1.30, revenue topped estimates

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin (NASDAQ: AMRN) reported Q2 2026 financial results with total net revenue of $42.2 million, a 42% year-over-year decrease primarily due to the absence of a prior-year upfront payment. Despite this, the company saw a 59% rise in global in-market demand for VASCEPA/VAZKEPA, with …

Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?

Biogen (BIIB) reported Q2 2026 revenue growth to US$2.74 billion, up from US$2.65 billion year-over-year, but net income sharply compressed to US$97.5 million from US$4.33 million the previous year. This earnings compression, despite revenue increases, is raising questions about future profitability, especially as the …

Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement

Johnson & Johnson has proposed a $5.5 billion settlement to resolve tens of thousands of ovarian cancer talc lawsuits, aiming to conclude a decade-long legal dispute. This settlement, if approved by a majority of claimants, could provide Johnson & Johnson with more predictability regarding …